Holocene Advisors Adds $11M in Glaukos Corporation ($GKOS)
Key Points
- Holocene Advisors changed its Glaukos Corporation ($GKOS) stake by 6.5% last quarter, boosting to 1,383,715 shares worth $175.47 million.
- Wall Street's consensus rating on $GKOS is Strong Buy and an average price target of $156.33.
- $GKOS last traded around $126.81.
Holocene Advisors increased its position in Glaukos Corporation ($GKOS) by 6.5% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,383,715 shares of Glaukos Corporation after buying 84,421 shares during the quarter. Holocene Advisors's holdings in Glaukos Corporation were worth $175.47 million as of its most recent filing.
Glaukos Corporation ($GKOS) Stock
Glaukos Corporation Earnings
Analysts Set New Price Targets
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.